- Home
- HQL vs HRTX Comparison
HQL vs HRTX Comparison
Compare HQL & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- HRTX
- Stock Information
- Founded
- HQL 1992
- HRTX 1983
- Country
- HQL United States
- HRTX United States
- Employees
- HQL N/A
- HRTX N/A
- Industry
- HQL Investment Managers
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- HQL Finance
- HRTX Health Care
- Exchange
- HQL Nasdaq
- HRTX Nasdaq
- Market Cap
- HQL 369.6M
- HRTX 325.0M
- IPO Year
- HQL N/A
- HRTX 1987
- Fundamental
- Price
- HQL $13.25
- HRTX $1.79
- Analyst Decision
- HQL
- HRTX Strong Buy
- Analyst Count
- HQL 0
- HRTX 2
- Target Price
- HQL N/A
- HRTX $5.00
- AVG Volume (30 Days)
- HQL 120.9K
- HRTX 1.0M
- Earning Date
- HQL 01-01-0001
- HRTX 08-11-2025
- Dividend Yield
- HQL 11.56%
- HRTX N/A
- EPS Growth
- HQL N/A
- HRTX N/A
- EPS
- HQL 0.79
- HRTX N/A
- Revenue
- HQL N/A
- HRTX $148,518,000.00
- Revenue This Year
- HQL N/A
- HRTX $12.08
- Revenue Next Year
- HQL N/A
- HRTX $12.57
- P/E Ratio
- HQL $17.08
- HRTX N/A
- Revenue Growth
- HQL N/A
- HRTX 12.43
- 52 Week Low
- HQL $11.34
- HRTX $1.04
- 52 Week High
- HQL $14.37
- HRTX $3.01
- Technical
- Relative Strength Index (RSI)
- HQL 54.37
- HRTX 31.83
- Support Level
- HQL $13.25
- HRTX $1.87
- Resistance Level
- HQL $13.44
- HRTX $1.93
- Average True Range (ATR)
- HQL 0.24
- HRTX 0.08
- MACD
- HQL -0.01
- HRTX -0.03
- Stochastic Oscillator
- HQL 57.85
- HRTX 4.17
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.